Best Practices and Research Advances in Thoracic Oncology: A Regional Series SE Asia Course 3: Driver Alterations in Lung Cancer-Adjuvant Treatment from EGFR to Other Biomarkers

Adjuvant Treatment from EGFR to Other Biomarkers

Video Transcription

Video Summary

Sunmin Lim, an associate professor from Yonsei University, discusses advancements in adjuvant treatments for non-small cell lung cancer. The presentation highlights how adjuvant therapies, like osimertinib for EGFR mutations and alektinib for ALK-positive patients, improve disease-free and overall survival, now becoming standard care for resected stage 1b to 3a patients. There are ongoing considerations about the role of adjuvant therapies in earlier stages or post-recurrence, and the potential to extend targeted treatments to these settings could enhance cure rates for oncogene-driven lung cancer.

Asset Subtitle

Sun Min Lim, MD, PhD

Keywords

adjuvant treatments

non-small cell lung cancer

osimertinib

EGFR mutations

ALK-positive